Retatrutide vs Tirzepatide vs Semaglutide: A Research Comparison

Few compound families have moved from bench to headline as quickly as the incretin receptor agonists. Three names dominate the current literature on metabolic and body-weight research: retatrutide, tirzepatide and semaglutide. They are frequently grouped together because they share a lineage in glucagon-like peptide 1 (GLP-1) biology, yet they differ in a way that matters a great deal to researchers: how many receptors each one engages. Semaglutide is a single-receptor GLP-1 agonist, tirzepatide is a dual GIP/GLP-1 agonist, and retatrutide adds a third arm by also engaging the glucagon receptor.

This comparison is written for people trying to place these molecules relative to one another in the scientific record. It focuses on mechanism, developmental stage and the strength of the evidence behind each, rather than on any individual protocol.

Research-only notice. This article is educational and describes compounds studied in laboratory and clinical research. Semaglutide and tirzepatide are approved prescription medicines in some jurisdictions; retatrutide is an investigational compound that is not approved for human use. Nothing here is medical advice, a recommendation, or dosing guidance. Any use of these compounds should occur only under qualified medical or licensed research supervision.

Mechanism: one receptor, two, or three

The clearest way to separate these compounds is by receptor coverage. Semaglutide is a GLP-1 analogue sharing roughly 94% sequence homology with native GLP-1. It selectively activates the GLP-1 receptor, which in research models promotes glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon, slows gastric emptying and reduces food intake through central pathways. A C18 fatty-diacid chain drives albumin binding, protecting it from rapid degradation and extending its half-life from the roughly two-minute window of native GLP-1 to about seven days.

Tirzepatide keeps GLP-1 activity and adds agonism at the glucose-dependent insulinotropic polypeptide (GIP) receptor. Pharmacology work by Coskun and colleagues characterised it as a single peptide acting at both receptors, and later studies described it as an imbalanced or biased agonist that engages GIP more strongly relative to GLP-1. The working hypothesis in the literature is that combined incretin signalling exceeds GLP-1 stimulation alone.

Retatrutide extends the concept a step further, adding the glucagon receptor to the GIP and GLP-1 arms. The glucagon component is of particular research interest because glucagon-receptor agonism is associated with increased energy expenditure and hepatic lipid handling, potentially complementing the appetite- and glucose-related effects of the incretin arms. Receptor-potency data indicate retatrutide is comparatively more potent at the GIP receptor and relatively less potent at the glucagon and GLP-1 receptors than the endogenous ligands, an intentional balancing act. Note that retatrutide is sometimes informally labelled “GLP-3” in popular writing; this is a marketing shorthand, not a recognised hormone class, and it is more accurately described as a triple agonist.

Evidence and development status

These three sit at very different points on the development curve, and that gap is the single most important thing to understand about them.

Semaglutide has the deepest and longest evidence base. Its programme spans glycaemic-control trials (the SUSTAIN series), dedicated body-weight trials (the STEP series, in which the 2.4 mg dose was associated with roughly 15% mean weight reduction versus placebo in adults with obesity), and a cardiovascular-outcomes trial (SELECT) reporting a reduction in major adverse cardiovascular events in overweight or obese participants without diabetes. That breadth, including hard outcome endpoints, is why it is often treated as the reference comparator.

Tirzepatide has a complete Phase 3 record across the SURPASS diabetes trials and the SURMOUNT obesity trials. In SURMOUNT-1, mean weight reductions of roughly 16% to 22.5% were reported across ascending dose levels in adults with obesity or overweight. Head-to-head work against semaglutide has also been published, extending the direct comparative literature that most novel agents lack at this stage.

Retatrutide is the newcomer and the least mature. Its published human record consists of Phase 1 pharmacology and safety work (Urva and colleagues, 2022) and Phase 2 trials: an obesity trial (Jastreboff and colleagues, 2023) reporting substantial dose-dependent weight reduction over 48 weeks, a type 2 diabetes trial (Rosenstock and colleagues, 2023), and a Phase 2a study in metabolic dysfunction-associated steatotic liver disease. Phase 2 results have generated considerable interest, but the compound has not completed the large Phase 3 outcome trials that anchor the other two, and it remains investigational.

Research context and safety signals

Across all three, the most consistently reported adverse events in trials are gastrointestinal, dose-dependent, generally mild to moderate, and tend to appear early and resolve. This is a class characteristic of incretin agonists rather than a distinguishing feature. The open questions differ by compound: for retatrutide they centre on how the added glucagon arm affects long-term safety, glycaemic variability and durability, which only Phase 3 and post-marketing data can answer. For tirzepatide and semaglutide, much current research explores indications beyond the original ones, including liver disease, cardiovascular and renal endpoints, and sleep apnoea.

Key differences

• Receptor count: semaglutide targets one receptor (GLP-1), tirzepatide two (GIP + GLP-1), retatrutide three (GIP + GLP-1 + glucagon).
• Maturity: semaglutide has the largest evidence base including cardiovascular outcomes; tirzepatide has a completed Phase 3 programme; retatrutide is still investigational with Phase 2 data.
• The glucagon arm: only retatrutide engages the glucagon receptor, the mechanistic feature that most distinguishes it and the one carrying the most unresolved long-term questions.
• Half-life: all three are engineered for once-weekly dosing via fatty-acid/albumin-binding chemistry, at roughly 5 days (tirzepatide), 6 days (retatrutide) and 7 days (semaglutide).
• Regulatory footing: two are approved medicines in multiple markets; retatrutide is not approved anywhere.

Which for what research?

Framed strictly as a matter of research use rather than personal advice, the three map to different questions. Semaglutide is the natural reference point for work grounded in the deepest evidence base, especially where cardiovascular or long-duration outcome data matter, because its record is the most complete. Tirzepatide suits investigations into dual-incretin co-agonism and comparative-effectiveness questions, since it has both a finished Phase 3 programme and published head-to-head data. Retatrutide is the compound of interest for exploratory research into triple-agonism and the specific contribution of glucagon-receptor engagement to energy expenditure and hepatic endpoints, with the firm caveat that its evidence is early-stage and its long-term safety profile is not yet established. In short, the more receptors a molecule engages, the more novel the mechanism and the thinner the long-term data.

Put these side by side in the Compare Peptides tool.

Sources

• Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022. PubMed 36354040
• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PubMed 37366315
• Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. Lancet. 2023. PubMed 37385280
• Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist (tirzepatide): from discovery to clinical proof of concept. Mol Metab. 2018. PubMed 30473097
• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PubMed 35658024
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PubMed 33567185
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. PubMed 37952131